Maturation of overall survival (OS) in TIVO-3 with long-term follow-up.

Rini, BI; Pal, SK; Escudier, B; Atkins, MB; McDermott, DF; Verzoni, E; Porta, C; Kasturi, V; Hutson, TE

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):